Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab plus Low Dose Cytarabine in Older Untreated AML
NCT00528333Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Sep 2007
- Primary completion
- Aug 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lintuzumab in acute myeloid leukemia (AML), sponsored by Seagen Inc. Primary endpoint: Overall Survival at 12 months. Started Sep 2007; status: completed.
02
Drugs
lintuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00528333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00528333.